艾伯森公司近日明确表示，其承担的阿片类药物相关和解费用将不会对2025财年的关键财务指标——调整后税息折旧及摊销前利润以及调整后净利润——产生任何影响。
这一声明为投资者提供了清晰的财务指引，强调了公司核心业务的盈利能力和财务状况不受此次一次性事件的干扰。公司管理层预计，其运营业绩将保持稳健增长态势。
艾伯森公司近日明确表示，其承担的阿片类药物相关和解费用将不会对2025财年的关键财务指标——调整后税息折旧及摊销前利润以及调整后净利润——产生任何影响。
这一声明为投资者提供了清晰的财务指引，强调了公司核心业务的盈利能力和财务状况不受此次一次性事件的干扰。公司管理层预计，其运营业绩将保持稳健增长态势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.